This product is a synthetic peptide HIV fusion inhibitor, which can bind to the viral envelope glycoprotein and prevent the conformational changes necessary for the fusion of the virus and the cell membrane, thereby inhibiting the replication of HIV-1. Enfuvirtide is derived from an amino acid sequence in the HR2 domain of gp41, which prevents the interaction between HR1 and HR2 and the change of gp41 configuration by mimicking the activity of the HR2 domain and competing for binding to the HR1 domain of gp41, thereby preventing the fusion of the virus with the host cell.